I’m a weight-loss doctor. Here’s why I worry about GLP-1 ‘microdoses’
-
By
-
Jody Dushay
-
May 29, 2026
-
Clinical Scorecard: Concerns from a Weight Loss Specialist: The Risks of Microdosing GLP-1 Medications
At a Glance
| Category | Detail |
|---|
| Condition | |
| Key Mechanisms | GLP-1 receptor agonists for weight management and metabolic health; microdosing lacks evidence. |
| Target Population | |
| Care Setting | |
Key Highlights
- Microdosing GLP-1s lacks legitimate long-term data and definitions.
- FDA-approved doses of semaglutide and tirzepatide are the only rigorously studied options.
- Microdosing products are often compounded and not FDA-approved.
- Dosing adjustments should be made under medical supervision.
- Potential benefits of GLP-1 treatment extend beyond weight loss.
- Compounded GLP-1s pose unknown safety and efficacy risks.
Guideline-Based Recommendations
Diagnosis
- Assess obesity and weight-related metabolic diseases for GLP-1 therapy.
Management
- Use FDA-approved doses of semaglutide and tirzepatide for weight loss.
- Avoid microdosing compounded GLP-1s.
Monitoring & Follow-up
- Monitor patients closely for side effects and weight loss progress.
Risks
- Microdosing compounded GLP-1s poses unknown safety and efficacy risks.
Patient & Prescribing Data
Patients seeking weight loss and metabolic health improvement.
Individualize dosing under medical supervision to optimize treatment.
Clinical Best Practices
- Prescribe only FDA-approved GLP-1 therapies.
- Avoid compounded products for microdosing.
- Consider maintenance dosing adjustments under supervision.
Related Resources & Content
